The goal of RPCI's Preclinical Imaging Resource (PIR) is to advance small animal imaging methodology at the molecular, cellular and biosystem level. This is accomplished by facilitating development of novel basic science and clinical research, promoting advances in biotechnology, fostering development of new Pharmaceuticals and assessing in vivo drug delivery and therapeutic efficacy. The PIR currently offers customized magnetic resonance (MR) protocols designed to answer specific questions related to: (i) cancer detection, (ii) tumor vascular function, (iii) therapeutic response, (iv) animal phenotyping and (v) pharmacokinetic /pharmacodynamic modeling. In addition, the Resource provides whole-body fluorescence imaging of live animals and facilitates collaborative microPET research in conjunction with the University at Buffalo (UB).
The aim i s to provide readily available access and training to noninvasive, state-of-the-art in vivo imaging technologies at an affordable cost to CCSG members. The PIR is available 24 hours/day, 7 days/week. Three general types of MR services are offered: (a) instrumentation and expertise to acquire high resolution (<50 urn2 in-plane spatial and <100 ms temporal) heteronuclear imaging and spectroscopy data, (b) expertise and software for quantitative image analysis and (c) visualization of 2D and 3D data sets for probing structural/functional relationships. MR instrumentation includes a 4.7 T wide bore (33 cm) magnet incorporating Bruker's Avance platform with ParaVision? 4.0 OS, shielded Accustar gradients and digital system electronics. The MR system represents the highest magnetic field strength scanner available within 200 miles of RPCI. Recently expanded services include whole body in vivo optical and multispectral fluorescence imaging. Intravital Microscopy (IVM) using a MR compatible window chamber is also available for fluorescence imaging with MR validation. Data acquisition, hardcopy, display, qualitative/quantitative analysis and 3D renderings of digitally acquired data sets are offered as chargeback services. The Resource is used by five programs and 99% of users are CCSG members. $65,218 in CCSG support is requested, representing 12% of the total operating budget.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Ciamporcero, Eric; Miles, Kiersten Marie; Adelaiye, Remi et al. (2015) Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther 14:101-10
Ma, Yingyu; Hu, Qiang; Luo, Wei et al. (2015) 1?,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells. J Steroid Biochem Mol Biol 148:166-71
Shen, Li; Sundstedt, Anette; Ciesielski, Michael et al. (2015) Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res 3:136-48
Adelaiye, Remi; Ciamporcero, Eric; Miles, Kiersten Marie et al. (2015) Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Mol Cancer Ther 14:513-22
Uekusa, Shota; Kawashima, Hiroyuki; Sugito, Kiminobu et al. (2014) Nr4a3, a possibile oncogenic factor for neuroblastoma associated with CpGi methylation within the third exon. Int J Oncol 44:1669-77
Ambrosone, Christine B; Zirpoli, Gary; Ruszczyk, Melanie et al. (2014) Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women's Circle of Health Study. Cancer Causes Control 25:259-65
Röhm, Marc; Grimm, Melissa J; D'Auria, Anthony C et al. (2014) NADPH oxidase promotes neutrophil extracellular trap formation in pulmonary aspergillosis. Infect Immun 82:1766-77
Rohrbach, Daniel J; Muffoletto, Daniel; Huihui, Jonathan et al. (2014) Preoperative mapping of nonmelanoma skin cancer using spatial frequency domain and ultrasound imaging. Acad Radiol 21:263-70
Ambrosone, Christine B; Young, Allyson C; Sucheston, Lara E et al. (2014) Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry. Oncotarget 5:237-48
O'Brien, Shalana; Golubovskaya, Vita M; Conroy, Jeffrey et al. (2014) FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics. Oncotarget 5:7945-59

Showing the most recent 10 out of 517 publications